CAMBRIDGE, MA, Launchpad Therapeutics, an antibody-focused precision oncology company, has raised $30M in Series A.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, announced the formation of Launchpad Therapeutics, Inc. (Launchpad), an antibody-focused precision oncology company, together with a $30 million Series A investment by founding investors, Versant Ventures and New Enterprise Associates (NEA).
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
